Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Alcohol warnings on analgesics

This article was originally published in The Tan Sheet

Executive Summary

Alcohol warnings on analgesics: "Each of the currently marketed OTC analgesic/antipyretic drug products may potentiate health risks" among individuals with history of heavy alcohol use or abuse, says FDA Division of OTC Drug Products Director Debra Bowen, MD, in Sept. 23 letter to Thomas Bryant, MD, president of Aspirin Foundation of America, responding to comments on the proposal ("The Tan Sheet" Aug. 19, p. 8). Yet-to-be-published proposed rule requiring warning "is not based on a desire for uniformity in the labeling" of OTC drugs, but rather on concern that warnings only on selective products may lead alcohol users "to conclude that a particular OTC analgesic is safer for their use," Bowen explains...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS086262

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel